| Antibiotics |
1 |
1 |
| Acute Kidney Injury |
0 |
0.46 |
| Clinical Guidelines |
0 |
0.46 |
| Pseudomonas Aeruginosa Infection |
0 |
0.46 |
| Bacteria |
0 |
0.35 |
| Gram-Negative Bacteria |
0 |
0.33 |
| Acinetobacter |
0 |
0.23 |
| Antibiotic Resistance |
0 |
0.23 |
| Injury |
0 |
0.23 |
| Kidney |
0 |
0.23 |
| Renal Failure |
0 |
0.23 |
| Hospital-Acquired Infection |
0 |
0.2 |
| Coronary Artery Disease (CAD) |
0 |
0.16 |
| Antibacterial Agents |
0 |
0.12 |
| Centers for Disease Control and Prevention |
0 |
0.12 |
| Drug Resistance |
0 |
0.12 |
| Escherichia coli |
0 |
0.12 |
| Europe |
0 |
0.12 |
| Heart |
0 |
0.12 |
| Hospital |
0 |
0.12 |
| Klebsiella Infections |
0 |
0.12 |
| Microbicides |
0 |
0.12 |
| Microbiology |
0 |
0.12 |
| Pandemic |
0 |
0.12 |
| Shock |
0 |
0.12 |
| Spine |
0 |
0.12 |
| Staphylococcus Aureus Infection |
0 |
0.12 |
| Washington |
0 |
0.12 |
| Wound Management |
0 |
0.11 |
| COVID-19 |
0 |
0.06 |
| Microbiome |
0 |
0.06 |
| Sepsis |
0 |
0.06 |
| Staphylococcal Infection |
0 |
0.06 |